Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Inflammatory Breast Cancer (IBC)”

19 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 19 of 19 results

Testing effectiveness (Phase 2)Study completedNCT02876302
What this trial is testing

Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer

Who this might be right for
Inflammatory Breast Cancer (IBC)
Dana-Farber Cancer Institute 23
Testing effectiveness (Phase 2)Ended earlyNCT03184558
What this trial is testing

Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC

Who this might be right for
Triple Negative Breast CancerInflammatory Breast Cancer Stage IV
BerGenBio ASA 29
Not applicableStudy completedNCT00646555
What this trial is testing

Inflammatory Breast Cancer, Tumor Markers, and Factors Associated With Angiogenesis

Who this might be right for
Breast Neoplasms
National Cancer Institute (NCI) 300
Testing effectiveness (Phase 2)Active Not RecruitingNCT02411656
What this trial is testing

Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy

Who this might be right for
EdemaErythemaEstrogen Receptor Negative+6 more
M.D. Anderson Cancer Center 71
Not applicableLooking for participantsNCT00477100
What this trial is testing

Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients With Inflammatory or Invasive Breast Cancer

Who this might be right for
Inflammatory Breast CarcinomaInvasive Breast CarcinomaSecond Primary Malignant Neoplasm
M.D. Anderson Cancer Center 1,200
Testing effectiveness (Phase 2)Study completedNCT01036087
What this trial is testing

Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer

Who this might be right for
Breast Cancer
M.D. Anderson Cancer Center 47
Testing effectiveness (Phase 2)Ended earlyNCT02892734
What this trial is testing

Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer

Who this might be right for
HER2/Neu NegativeRecurrent Inflammatory Breast CarcinomaStage IV Breast Cancer+1 more
Northwestern University 3
Not applicableLooking for participantsNCT07080944
What this trial is testing

Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in IBC

Who this might be right for
Invasive Breast CarcinomaSentinel Lymph Node Biopsy (SLNB)Neoadjuvant Chemotherapy
European Institute of Oncology 75
Testing effectiveness (Phase 2)Ended earlyNCT00756470
What this trial is testing

Phase II Neoadjuvant in Inflammatory Breast Cancer

Who this might be right for
Breast Cancer
M.D. Anderson Cancer Center 15
Testing effectiveness (Phase 2)Active Not RecruitingNCT02971748
What this trial is testing

Pembrolizumab in Treating Patients With Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy

Who this might be right for
Anatomic Stage IIIB Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8Breast Inflammatory Carcinoma+2 more
M.D. Anderson Cancer Center 36
Not applicableLooking for participantsNCT04636710
What this trial is testing

Refining Local-Regional Therapy for IBC

Who this might be right for
Breast CancerInflammatory Breast CancerSentinel Lymph Node
Dana-Farber Cancer Institute 50
Testing effectiveness (Phase 2)Ended earlyNCT02389764
What this trial is testing

Nintedanib For HER2-Negative Metastatic Inflammatory Breast Cancer (MIBC)

Who this might be right for
Breast Cancer
M.D. Anderson Cancer Center 10
Testing effectiveness (Phase 2)WithdrawnNCT05177796
What this trial is testing

Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8+10 more
M.D. Anderson Cancer Center
Testing effectiveness (Phase 2)Study completedNCT00016549
What this trial is testing

Bevacizumab to Treat Inflammatory Breast Cancer or Locally Advanced Breast Cancer

Who this might be right for
Breast Cancer
National Cancer Institute (NCI) 21
Testing effectiveness (Phase 2)Looking for participantsNCT05795101
What this trial is testing

TRUDI: TDXD+Durva in HER2+/Low IBC

Who this might be right for
Invasive Breast CancerInflammatory Breast Cancer Stage IIIHER2-positive Breast Cancer+2 more
Filipa Lynce, MD 63
Testing effectiveness (Phase 2)Study completedNCT03742986
What this trial is testing

Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC)

Who this might be right for
Breast Cancer
NYU Langone Health 8
Testing effectiveness (Phase 2)Ended earlyNCT03101748
What this trial is testing

Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer

Who this might be right for
Breast Inflammatory CarcinomaLocally Advanced Breast CarcinomaMetastatic Breast Carcinoma+5 more
M.D. Anderson Cancer Center 34
Testing effectiveness (Phase 2)Study completedNCT01262027
What this trial is testing

TKI258 for Metastatic Inflammatory Breast Cancer Patients

Who this might be right for
Breast Cancer
M.D. Anderson Cancer Center 22
Testing effectiveness (Phase 2)Ended earlyNCT02658812
What this trial is testing

Talimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be Removed by Surgery

Who this might be right for
Malignant Chest Wall NeoplasmRecurrent Breast CarcinomaRecurrent Inflammatory Breast Carcinoma+2 more
M.D. Anderson Cancer Center 11